A Polesky, HW Farber, DJ Gottlieb, H Park, S Levinson, JJ O'Connell, B McInnis, RL Nieves and J Bernardo
Department of Medicine, Boston University School of Medicine, Massachusetts, USA.

An epidemic of isoniazid (INH)- and streptomycin (SM)-resistant tuberculosis began among Boston's homeless population in 1984. Individuals with skin test conversions who agreed to preventive therapy received either INH, rifampin, or a combination of INH and rifampin. A total of 204 individuals with documented tuberculin skin test conversions who did not have active tuberculosis at the time of the clinical evaluation for their positive skin test were eligible for preventive therapy. Data on type and length of preventive therapy were obtained from the Tuberculosis Clinic and the Boston Tuberculosis Registry records at Boston City Hospital. The individuals were followed for development of active tuberculosis. Six of 71 (8.6%) individuals who received no therapy, 3 of 38 (7.9%) in the INH group, and none in the rifampin or rifampin plus INH groups (49 and 37 persons, respectively) developed active tuberculosis. Patients in the rifampin group were significantly less likely to develop tuberculosis than patients in the no therapy group (p = 0.04; odds ratio [OR] = 0.00, 95% confidence interval [CI] = 0.00-0.91). Treatment with any rifampin- containing preventive therapy (rifampin or rifampin plus INH) was effective (p < 0.01 ) in preventing development of active disease. The three INH failures were with organisms that were resistant to INH.

This article has been cited by other articles:

				D. Menzies, R. Long, A. Trajman, M.-J. Dion, J. Yang, H. Al Jahdali, Z. Memish, K. Khan, M. Gardam, V. Hoeppner, et al. Adverse Events with 4 Months of Rifampin Therapy or 9 Months of Isoniazid Therapy for Latent Tuberculosis Infection: A Randomized Trial Ann Intern Med, November 18, 2008; 149(10): 689 - 697. [Abstract] [Full Text] [PDF]

				H. M. Blumberg Needed: New and Better Tools to Combat Latent Tuberculosis Infection Ann Intern Med, November 18, 2008; 149(10): 761 - 763. [Full Text] [PDF]

				A. Lardizabal, M. Passannante, F. Kojakali, C. Hayden, and L. B. Reichman Enhancement of Treatment Completion for Latent Tuberculosis Infection With 4 Months of Rifampin Chest, December 1, 2006; 130(6): 1712 - 1717. [Abstract] [Full Text] [PDF]

				J. J. Saukkonen, D. L. Cohn, R. M. Jasmer, S. Schenker, J. A. Jereb, C. M. Nolan, C. A. Peloquin, F. M. Gordin, D. Nunes, D. B. Strader, et al. An Official ATS Statement: Hepatotoxicity of Antituberculosis Therapy. Am. J. Respir. Crit. Care Med., October 15, 2006; 174(8): 935 - 952. [Abstract] [Full Text] [PDF]

				K. R. Page, F. Sifakis, R. Montes de Oca, W. A. Cronin, M. C. Doherty, L. Federline, S. Bur, T. Walsh, W. Karney, J. Milman, et al. Improved Adherence and Less Toxicity With Rifampin vs Isoniazid for Treatment of Latent Tuberculosis: A Retrospective Study. Arch Intern Med, September 25, 2006; 166(17): 1863 - 1870. [Abstract] [Full Text] [PDF]

				H. M. Blumberg, M. K. Leonard Jr, and R. M. Jasmer Update on the Treatment of Tuberculosis and Latent Tuberculosis Infection JAMA, June 8, 2005; 293(22): 2776 - 2784. [Abstract] [Full Text] [PDF]

				L. B. Reichman, A. Lardizabal, and C. H. Hayden Considering the Role of Four Months of Rifampin in the Treatment of Latent Tuberculosis Infection Am. J. Respir. Crit. Care Med., October 15, 2004; 170(8): 832 - 835. [Full Text] [PDF]

				D. Menzies, M.-J. Dion, B. Rabinovitch, S. Mannix, P. Brassard, and K. Schwartzman Treatment Completion and Costs of a Randomized Trial of Rifampin for 4 Months versus Isoniazid for 9 Months Am. J. Respir. Crit. Care Med., August 15, 2004; 170(4): 445 - 449. [Abstract] [Full Text] [PDF]

				S. M. Marks, K. Ijaz, M. F. Iademarco, T. Sterling, S. S. Munsiff, T. R. Frieden, D. Menzies, K. Schwartzman, E. R. Jenny-Avital, K. Khan, et al. Management of Latent Tuberculosis Infection in Immigrants N. Engl. J. Med., March 27, 2003; 348(13): 1289 - 1292. [Full Text] [PDF]

				P T Heath and A S Breathnach Treatment of infections due to resistant organisms: Childhood respiratory infections Br. Med. Bull., March 1, 2002; 61(1): 231 - 245. [Abstract] [Full Text] [PDF]

				T. F. Brewer, S. J. Heymann, S. M. Krumplitsch, M. E. Wilson, G. A. Colditz, and H. V. Fineberg Strategies to Decrease Tuberculosis in US Homeless Populations: A Computer Simulation Model JAMA, August 15, 2001; 286(7): 834 - 842. [Abstract] [Full Text] [PDF]

				B. D. McNAB, D. D. MARCINIUK, R. A. ALVI, L. TAN, and V. H. HOEPPNER Twice Weekly Isoniazid and Rifampin Treatment of Latent Tuberculosis Infection in Canadian Plains Aborigines Am. J. Respir. Crit. Care Med., September 1, 2000; 162(3): 989 - 993. [Abstract] [Full Text]

				Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection . This Official Statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This Statement was endorsed by the Council of the Infectious Diseases Society of America (IDSA), September 1999, and the sections of this Statement as it relates to infants and children were endorsed by the American Academy of Pediatrics (AAP), August 1999. Am. J. Respir. Crit. Care Med., April 1, 2000; 161(4): S221 - 247. [Full Text] [PDF]

				Joint Tuberculosis Committee of the British Thorac Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998 Thorax, July 1, 1998; 53(7): 536 - 548. [Abstract] [Full Text]